1. Home
  2. ORGN vs CRDL Comparison

ORGN vs CRDL Comparison

Compare ORGN & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Origin Materials Inc.

ORGN

Origin Materials Inc.

HOLD

Current Price

$0.48

Market Cap

109.4M

Sector

Industrials

ML Signal

HOLD

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

HOLD

Current Price

$1.04

Market Cap

97.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORGN
CRDL
Founded
2008
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
109.4M
97.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ORGN
CRDL
Price
$0.48
$1.04
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$9.00
AVG Volume (30 Days)
978.9K
400.0K
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$25,122,000.00
N/A
Revenue This Year
$49.18
N/A
Revenue Next Year
$144.81
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.40
$0.77
52 Week High
$1.36
$1.67

Technical Indicators

Market Signals
Indicator
ORGN
CRDL
Relative Strength Index (RSI) 41.03 49.31
Support Level $0.41 $0.94
Resistance Level $0.49 $1.04
Average True Range (ATR) 0.04 0.06
MACD -0.00 0.00
Stochastic Oscillator 39.80 76.92

Price Performance

Historical Comparison
ORGN
CRDL

About ORGN Origin Materials Inc.

Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others by using materials like food and beverage packaging, clothing, textiles, plastics, car parts, carpeting, tires, adhesives, soil amendments, and fuels.

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Share on Social Networks: